Karyopharm Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated Advanced Dedifferentiated Liposarcoma
Go back to Karyopharm Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated Advanced Dedifferentiated Liposarcoma| KARYOPHARM THERAP (NASDAQ: KPTI) | Delayed: 7.18 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.18 | 52 Week High | $19.41 | |||
| Open | $7.18 | 52 Week Low | $4.83 | |||
| Day High | $7.18 | P/E | N/A | |||
| Day Low | $7.18 | EPS | $-2.74 | |||
| Volume | 367 | |||||
